Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
Source ↗
👁 0
💬 0
Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline®, growing by 27.5% at CER
Strong pipeline momentum with three Phase III readouts expected in H2 2026
Confirmation of full-year 2026 guidance2
PARIS, FRANCE, 23 April 2026 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026.
Q1 2026
% change
Strong pipeline momentum with three Phase III readouts expected in H2 2026
Confirmation of full-year 2026 guidance2
PARIS, FRANCE, 23 April 2026 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026.
Q1 2026
% change
Comments (0)